NCT07352592 Process-Based Approach Case Series For Anxiety Problems
| NCT ID | NCT07352592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Anxiety |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-06-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A case series of PBA intervention for anxiety problems.
Eligibility Criteria
Inclusion Criteria: * Score on GAD-7 \>10 at baseline * Access to mobile device Exclusion Criteria: * Current psychotherapy treatment * Current/past severe psychopathology (e.g., history of psychosis, suicide attempt or self-injury within the past 12 months, narcotics use within the past 3 months)
Contact & Investigator
Nicholas C Borgogna, PhD
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT07352592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07352592 currently recruiting?
Yes, NCT07352592 is actively recruiting participants. Contact the research team at whitdrew@uab.edu for enrollment information.
Where is the NCT07352592 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT07352592 clinical trial?
NCT07352592 is sponsored by University of Alabama at Birmingham. The principal investigator is Nicholas C Borgogna, PhD at University of Alabama at Birmingham. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.